According to Zhitong Finance App, Jinling Pharmaceutical (000919.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,584 billion yuan, a year-on-year decrease of 1.04%; net profit attributable to shareholders of listed companies was 50,382,500 yuan, an increase of 4.24% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 489.12,800 yuan, an increase of 37.74% year on year; basic earnings per share were 0.081 yuan.

During the reporting period, the company's “Pharmaceutical Industry and Medical Care” platforms worked simultaneously and collaboratively. In the pharmaceutical industry sector, the company closely focuses on the overall goal of “steady growth, cost reduction, structural adjustment, and capacity improvement” to promote the two main lines of production, operation and market expansion in an integrated manner; in the medical care sector, medical institutions continue to promote the in-depth development of lean management in accordance with annual business goals, and basic diagnosis and treatment indicators such as the number of outpatient emergency patients, hospitalizations, and surgery volume of various medical institutions are generally rising steadily.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.